Metabolomics is the systematic study of the small-molecule repertoire that a biological system produces and consumes at a given moment. Because the metabolome captures the integrated output of genome, transcriptome, and proteome, it offers an unusually direct window onto phenotype, and demands on its measurement platforms are correspondingly high. A single instrument rarely covers the full chemical space that biology produces, which is why modern metabolomics combines several complementary analytical approaches rather than relying on any one platform. Understanding the principles, characteristics, and applications of these approaches is the most reliable way to choose the right tool for a given biological question.
Metabolomics is the analytical discipline that identifies and quantifies the complete set of low-molecular-weight metabolites, generally under 1,500 Da, present in a biological sample. Unlike genomics or transcriptomics, which describe the system's potential, metabolomics reports its actual biochemical state, including the cumulative influence of nutrition, environment, microbiome, and pharmacological intervention. The metabolome is therefore treated as the most chemically varied of the “omics” layers, spanning organic acids, amino acids, lipids, nucleotides, sugars, vitamins, cofactors, bile acids, acylcarnitines, signaling molecules, and many exogenous species from drugs to dietary components.
In a modern laboratory three strategies coexist and are routinely chosen according to the question being asked:
Metabolomics measures the entire small-molecule chemistry of the biological system, ranging from the dominant central carbon metabolites that fuel energy production to the low-abundance signaling lipids and modified nucleotides that orchestrate cellular responses. Because metabolic classes differ widely in polarity, volatility, ionic character, and dynamic range, no single sample preparation or analytical column covers them all. Successful programs use sample preparation workflows and platform choices that are matched to the chemical class of interest. The categories most often encountered, and the platforms that handle them best, are summarized in the table below.
Table.1 Major Metabolite Categories and the Analytical Platforms Most Often Applied to Them.
| Metabolite Category | Representative Species | Commonly Used Platforms |
| Amino acids and derivatives | 20 proteinogenic amino acids, neurotransmitter-related species (GABA, 5-HT, dopamine), one-carbon metabolites | LC-MS/MS, GC-MS |
| Lipids (lipidomics subset) | Phospholipids, triglycerides, cholesteryl esters, sphingolipids, fatty acids, eicosanoids | LC-MS, SFC-MS |
| Organic acids | TCA cycle intermediates, short-chain fatty acids (acetate, propionate, butyrate), ketone bodies | GC-MS, CE-MS |
| Carbohydrates and glycolytic intermediates | Glucose, lactate, pyruvate, phosphorylated sugars | GC-MS, HILIC-LC-MS, CE-MS |
| Nucleotides and coenzymes | ATP/ADP/AMP, NAD+/NADH, CoA-class molecules | CE-MS, LC-MS |
| Vitamins and cofactors | B-class vitamins, vitamin D metabolites, thiamine derivatives | LC-MS/MS |
| Bile acids | Primary and secondary bile acids, glycine and taurine conjugates | LC-MS/MS |
| Acylcarnitines | Free carnitine, C2–C18 acylcarnitines (indices of fatty-acid oxidation) | LC-MS/MS (MRM) |
| Nucleosides and related species | Uridine, inosine, purine metabolites (uric acid, xanthine) | LC-MS |
| Xenobiotics and exposure markers | Drugs and their metabolites, food-derived species, environmental exposure signatures | LC-HRMS |
| Volatile metabolites | Exhaled volatile organic compounds, microbiota-derived gases | GC-MS, SPME-GC-MS |
Metabolomics accepts a remarkably broad set of biological sample types, and each carries its own pre-analytical considerations that influence analytical choice:
A complete metabolomics measurement simultaneously yields three categories of information that together describe what the sample contains, how much is present, and how the molecules are flowing through the system.
NMR occupies a distinctive place in metabolomics because it measures metabolites directly from a complex mixture without separation, with signal intensities proportional to molar concentration, and with structural information encoded in the resonance pattern itself. The technique is built on the interaction between nuclear spins, primarily 1H and 13C, and a strong external magnetic field, and it serves both as a discovery tool and as a definitive confirmation method when structural identity is in doubt.
The NMR experiment places the sample in a homogeneous magnetic field and applies a short radio-frequency pulse that excites the nuclear spins of the molecules present. As the excited population relaxes back to equilibrium, each nucleus re-emits a radio signal whose frequency, the chemical shift, reflects the local electronic environment of the atom within its molecule. Because every chemically distinct nucleus produces its own resonance, the resulting spectrum is a one-to-one fingerprint of all soluble metabolites carrying NMR-active nuclei, and signal area is directly proportional to the number of contributing nuclei, which is the basis for the technique's intrinsic quantitation.
Two experimental families dominate metabolomics applications:
NMR has a profile that complements rather than competes with mass spectrometry. Its defining features are high reproducibility across laboratories and instruments, non-destructive analysis that lets the sample be recovered for follow-up measurements, minimal sample preparation typically limited to buffer exchange and a stable isotope reference compound, and excellent quantitative precision due to the linear, concentration-proportional signal response. The technique handles a wide variety of biofluids and tissue extracts with similar workflows, and high-resolution magic-angle spinning (HR-MAS) experiments allow intact tissue biopsies to be analyzed with minimal preprocessing.
The principal limitation is sensitivity. State-of-the-art instruments detect metabolites reliably in the low micromolar (µM) range, which places them two to three orders of magnitude behind mass spectrometry. The result is a narrower accessible portion of the metabolome: highly abundant central-carbon species, organic acids, amino acids, osmolytes, and many intact lipids appear clearly, while low-abundance signaling lipids, hormones, and many drug-related species often remain below the detection floor. Other practical considerations include the large footprint and cost of high-field spectrometers and the dominance of water and other solvent signals, which require suppression routines that can attenuate nearby metabolite resonances.
NMR is most often chosen for applications where quantitative robustness, sample preservation, and unambiguous identification outweigh sensitivity concerns. Biofluid fingerprinting by 1H NMR generates stable, comparable profiles used in population-scale research and large cohort studies, while HR-MAS NMR maps metabolite distributions in intact tissue biopsies such as tumors and biopsy cores. Two-dimensional experiments provide definitive structural elucidation of unknown metabolites, isotopologue analysis in 13C tracer studies, and deconvolution of overlapping resonances in chemically complex matrices. Combined with multivariate statistics, NMR-derived profiles support biomarker discovery research, comparative studies across treatment groups, and longitudinal monitoring of metabolic phenotypes, and the technique's quantitative nature allows it to serve as a reference for cross-platform validation. BOC Sciences provides dedicated NMR testing services that span 1D and 2D experiments, HR-MAS tissue analysis, and quantitative structural elucidation for unknown metabolites.
Table.2 Representative NMR Experiments and Their Roles in Metabolomics.
| Experiment | Typical Output | Principal Use in Metabolomics |
| 1D 1H with water suppression | Quantitative metabolic fingerprint of a biofluid or extract | Routine profiling, cohort comparison, quality control of sample cohorts. |
| 2D 1H–13C HSQC | Carbon–proton connectivity map of a complex mixture or unknown | De novo structure elucidation, isotopic-tracer analysis, confirmation of novel metabolites. |
| 2D JRES or TOCSY | Spin-system networks resolving overlapping 1D resonances | Identification in crowded spectra, assignment of sugars and complex conjugates. |
| HR-MAS on intact tissue | High-resolution 1D and 2D spectra of biopsy material | Tissue metabolomics with preserved spatial architecture, tumor heterogeneity studies. |
| Quantitative 1H NMR with External Reference Calibration | Absolute concentrations without chemical standards of every analyte | Absolute quantitation of amino acids, organic acids, and energy metabolites. |
Our NMR team develops 1D/2D and HR-MAS workflows matched to biofluid, tissue, and quantitative profiling needs.
LC-MS is the workhorse platform of contemporary metabolomics, coupling a separation step that addresses the chemical heterogeneity of metabolite extracts with mass spectrometry that identifies and quantifies the separated species. Reversed-phase chromatography handles moderately polar to nonpolar analytes, hydrophilic interaction chromatography (HILIC) covers highly polar and ionic metabolites, and high-resolution mass analyzers furnish accurate-mass and MS/MS information that together support confident identification and reproducible quantification across thousands of features.
The metabolomics sample is injected onto a column whose chemistry is matched to the metabolites of interest. Reversed-phase separations, typically C18 with water/acetonitrile gradients, elute lipids, bile acids, and many drug-related species in order of decreasing polarity. HILIC separations, using polar stationary phases and high-acetonitrile mobile phases, retain and resolve sugars, organic acids, nucleotides, and polar amino acids that would otherwise elute unretained from reversed-phase columns. After separation, analytes are ionized by electrospray ionization (ESI) for polar species or atmospheric-pressure chemical ionization (APCI) for less polar metabolites, and the ions enter the mass spectrometer.
Inside the mass spectrometer, two analyzer classes dominate metabolomics:
LC-MS combines excellent sensitivity, typically in the pg to ng per mL range, with the broadest metabolite coverage of any single platform. The technique detects amino acids, organic acids, nucleotides, vitamins, bile acids, complex lipids, drug-related species, and many additional chemical classes within one instrument family, providing a continuous bridge across most of the metabolome. HRMS data are information-rich because every spectrum is recorded in full and can be re-interrogated after the run, which makes retargeted analysis of archived raw files possible without re-injecting samples.
Ion suppression from co-eluting matrix components and overall matrix effects require careful attention; isotope-labeled internal standards are routinely used to compensate. Sensitivity and coverage depend strongly on chromatographic conditions, so a single reversed-phase run typically captures less than 60% of the metabolome and is best paired with a complementary HILIC or ion-chromatography method for comprehensive coverage. Quantitative work also requires careful calibration, particularly for low-abundance species, and the dynamic range, while wide, is narrower than what triple-quadrupole targeted assays can achieve.
LC-MS is the platform most often selected when the analytical goal is broad discovery across a heterogeneous population of metabolites. Untargeted workflows compare full spectral profiles across sample groups to detect differentially abundant features, which are then identified through a combination of accurate-mass database matching, MS/MS spectral library comparison, retention-time alignment with authentic standards, and CCS-based confirmation. Once identities are assigned, the data are mapped onto metabolic pathways through enrichment analysis and topology-based algorithms, generating biological hypotheses for follow-up.
Targeted LC-MS/MS is then routinely used to verify the original findings with absolute quantification, and the same workflow supports panels for routine measurement of known biomarkers. The combination of untargeted LC-HRMS discovery followed by targeted LC-MS/MS confirmation is the dominant pattern in modern metabolomics research and in many translational research pipelines, where biomarker candidates must be validated across cohorts and over time. BOC Sciences supports both ends of this workflow through LC-MS testing and LC-MS/MS testing (see the service table below), including reversed-phase and HILIC profiling, untargeted HRMS workflows, and targeted MRM panels for amino acids, bile acids, acylcarnitines, vitamins, and other curated metabolite sets.
Discuss sample matrix, target list, and coverage goals with our LC-MS team and receive a tailored workflow proposal.
Gas chromatography-mass spectrometry, with its roots in early metabolomics research, remains one of the most reproducible and library-rich platforms in the field. The technique excels at volatile and thermally stable species and, after appropriate chemical derivatization, at a wide variety of primary metabolites including amino acids, organic acids, sugars, amines, and fatty acids. GC-MS is the historic workhorse of plant metabolomics and of central-carbon metabolite studies, and it continues to provide highly complementary data alongside LC-MS workflows.
A GC-MS analysis begins with sample extraction and a derivatization step that converts polar functional groups, including hydroxyl, carboxyl, amine, and thiol groups, into less polar, more thermally stable, and more volatile derivatives. Silylation, methoximation followed by trimethylsilylation, and methyl esterification are the most common chemistries. The derivatized extract is injected onto a capillary column with a temperature-programmed ramp that separates analytes principally by boiling point and secondarily by interaction with the stationary phase.
Detection uses electron impact (EI) ionization at the standardized 70 eV energy, which yields highly reproducible fragmentation patterns that match the major public mass spectral libraries. The same fragmentation physics makes spectra comparable across laboratories and across decades, supporting reproducible identification. Chemical ionization (CI) and time-of-flight (TOF) mass analyzers are increasingly used to add molecular-ion information and high acquisition rates for comprehensive two-dimensional separations.
GC-MS offers unmatched reproducibility for polar primary metabolites and access to the most mature commercial spectral libraries in metabolomics. Its EI fragmentation patterns are inherently reproducible, easing identification of unknown metabolites, while matrix effects are generally mild because the derivatization and temperature-programmed separation clean up many interfering components and provide high chromatographic peak capacity. Instrument costs are lower than for HRMS platforms, and quantitative precision after derivatization is excellent across the detectable range.
The most obvious constraint is that only analytes that are already volatile, or that can be made volatile through derivatization, are accessible. Large or labile molecules such as intact phospholipids, complex oligosaccharides, intact peptides, and many drugs and their conjugates are unsuitable targets. The derivatization step adds variability if not rigorously controlled, and certain important metabolite classes such as highly polar phosphorylated intermediates are difficult to capture by routine derivatization. Long analysis times, often twenty to forty minutes per run, also reduce throughput compared with flow-injection and short-gradient LC methods, although modern fast-GC protocols partially address this concern.
GC-MS is the dominant platform for a set of applications where its particular strengths are decisive. Volatile metabolite profiling through headspace or solid-phase microextraction captures the volatile fraction of biological samples, including exhaled breath volatiles, food aromas, microbial fermentation products, and environmental odor signatures. Derivatized GC-MS is the workhorse of central-carbon metabolic profiling, covering glycolysis, the TCA cycle, the pentose phosphate pathway, and amino acid and sugar pools with well-established extraction and derivatization protocols. BOC Sciences provides GC-MS testing for both volatile profiling and derivatized primary-metabolite panels, supporting plant, microbial, fermentation, and discovery research programs with widely adopted derivatization and headspace-SPME workflows.
Table.3 GC-MS Derivatization Strategies and the Metabolite Classes They Uncover.
| Derivatization Chemistry | Functional Groups Addressed | Representative Metabolite Classes |
| Methoximation followed by trimethylsilylation | Carbonyl groups protected, hydroxyl and amine groups silylated | Sugars, sugar phosphates, organic acids, amino acids. |
| Single-step trimethylsilylation | Hydroxyl, amine, thiol, and carboxyl groups | Broad primary metabolite coverage in established derivatization protocols. |
| Methyl esterification (e.g., BF3/methanol) | Carboxyl groups converted to methyl esters | Fatty acids, short-chain fatty acids, dicarboxylic acids. |
| Headspace or SPME (no derivatization) | Native volatility | Exhaled breath volatiles, fermentation off-gases, food aroma compounds. |
| tert-Butyldimethylsilyl derivatization | Hydroxyl, amine, carboxyl groups | Polyhydroxy acids, labile phosphorylated intermediates, isotope-tracer experiments. |
Our GC-MS team supports headspace, SPME, and derivatized central-carbon workflows across many sample types.
Capillary electrophoresis-mass spectrometry separates metabolites by their electrophoretic mobility in a high electric field, providing an orthogonal separation mechanism to chromatographic methods. CE-MS provides exceptional resolution for highly polar and ionic metabolites, captures species that are difficult to retain or resolve by reversed-phase LC, and operates with nanoliter-scale injection volumes that are valuable when sample is scarce.
CE separations occur in narrow capillaries filled with a background electrolyte. When high voltage is applied, cations migrate toward the cathode, anions toward the anode, and neutral species move with the electro-osmotic flow at a common velocity. The separation depends on charge-to-size ratio, with smaller and more highly charged ions migrating faster. Sheath-liquid or porous-tip interfaces deliver the eluent into the mass spectrometer while preserving the high voltage circuit and providing the make-up flow necessary for stable electrospray ionization.
Two modes are most often used in metabolomics:
CE-MS achieves a level of separation efficiency for small ions that is difficult to match by liquid chromatography, particularly for highly polar and charged species such as phosphorylated sugars, nucleotides, organic acids, and amino acids. The capillary format requires only nanoliters of sample per injection, which is critical for limited biopsy, microdissected, and single-cell applications. Because the separation mechanism is fundamentally different from reversed-phase or HILIC chromatography, CE-MS captures metabolites that may be lost or poorly resolved in LC workflows.
The technique also has well-known practical constraints. Migration times are sensitive to capillary surface chemistry, buffer composition, and adsorption phenomena, so they are less reproducible than chromatographic retention times, and run-to-run migration-time alignment requires careful conditioning and frequent internal-standard corrections. Coverage of neutral and hydrophobic species is poor, because lipids and other nonpolar metabolites have no significant electrophoretic mobility. Sensitivity, while improved by modern sheathless and nano-electrospray interfaces, remains lower than that of typical LC-MS workflows for many species.
CE-MS is the platform of choice for several demanding metabolite classes. Energy metabolism measurements, including adenosine phosphate pools (ATP/ADP/AMP), redox cofactors (NAD+/NADH, NADP+/NADPH), and glycolytic intermediates, are often handled with CZE–MS because these species are highly charged and difficult to retain by reversed-phase LC. CE-MS also supports cationic and anionic amino acid profiles, organic acid panels, and a growing body of single-cell metabolomics work, where its nanoliter injection volumes are essential. The platform complements LC-MS workflows rather than replacing them, and pairing CE-MS cation and anion profiles with LC-MS reversed-phase profiles for the same sample set has become a productive combined strategy for comprehensive metabolome coverage.
Discuss CE-MS workflows for energy metabolites, nucleotides, or single-cell samples with our analytical specialists.
Targeted LC-MS/MS delivers the absolute quantification that is required whenever precise concentrations drive decisions: validation of biomarker candidates, measurement of predefined metabolite panels, internal standards support for isotope-dilution methods, and pathway activity readouts. The platform is built around triple-quadrupole instruments operated in multiple reaction monitoring (MRM), and it provides the sensitivity, specificity, and dynamic range necessary for quantitative work over many orders of magnitude.
A targeted LC-MS/MS analysis separates the metabolite extract by liquid chromatography using reversed-phase or HILIC conditions chosen for the analyte panel, then introduces the eluent into a triple-quadrupole mass spectrometer. The first quadrupole (Q1) selects a predefined precursor ion corresponding to the target metabolite; the second quadrupole (Q2) serves as a collision cell in which the precursor is fragmented under controlled conditions; the third quadrupole (Q3) monitors one or more characteristic product ions. The pair (precursor, product) defines a transition, and the instrument visits many transitions in rapid succession, recording one or more signals per metabolite per cycle.
Quantification uses isotope-labeled internal standards for each analyte, typically 13C- or 15N-substituted analogues or deuterated versions, which compensate for matrix effects, recovery losses, and ion suppression. Calibration curves are constructed from authentic reference standards spiked into a surrogate matrix, and concentrations in unknown samples are back-calculated from the analyte/internal-standard ratio.
The defining strengths of targeted LC-MS/MS are quantitative accuracy, sensitivity, and dynamic range. Limits of quantitation reach the low nM to sub-ng/mL range in plasma, with five to six orders of magnitude of linear dynamic range, enabling simultaneous detection of low-abundance hormones and high-abundance housekeeping metabolites from a single injection. The MRM filtering of both precursor and product ion yields excellent selectivity even in complex matrices, and the isotope-dilution workflow produces concentrations traceable to authentic standards with high precision.
The principal limitation is the closed-list nature of the approach. Targeted LC-MS/MS only measures analytes whose transitions are programmed before the run, so it cannot detect unexpected metabolites or discover new biology. Method development is intensive, because each metabolite often requires its own chromatographic condition, transition optimization, and internal-standard validation. Cycle time across many transitions may also limit how many analytes can be measured per injection without sacrificing dwell time and signal quality.
Targeted LC-MS/MS is widely used to deliver routine panels for biomarker validation, including acylcarnitine and amino acid profiling, bile acid panels across the primary, secondary, and conjugated classes, vitamin and cofactor panels, neurotransmitter quantification, and short-chain fatty acid analysis. The same architecture supports pharmacokinetic analysis of drugs and their metabolites, exposure assessment for food- and environment-derived xenobiotics, and pathway activity measurements such as fatty acid oxidation flux or tryptophan-catabolism readouts. BOC Sciences supports targeted workflows through LC-MS/MS testing built around validated MRM panels for major metabolite classes, including access to custom-panel development for project-specific needs.
Table.4 Comparison of Major Analytical Approaches in Metabolomics.
| Platform | Separation Principle | Typical Coverage | Quantitative Strength | Principal Limitation |
| NMR | None (direct detection of spin resonances) | Highly abundant polar metabolites, dominant lipid classes | Intrinsically quantitative, excellent precision | Lower sensitivity (µM range); high instrument cost |
| LC-HRMS (untargeted) | Reversed-phase or HILIC chromatography | Broadest accessible metabolite range | Retrospective re-interrogation of archived data | Matrix effects; coverage depends on chromatographic conditions |
| Targeted LC-MS/MS (MRM) | Reversed-phase or HILIC chromatography | Closed list of predefined analytes | Best sensitivity, specificity, and dynamic range | Cannot discover unexpected metabolites; intensive method development |
| GC-MS | Capillary gas chromatography with temperature programming | Volatile species and derivatized primary metabolites | Reproducible EI fragmentation; mature libraries | Restricted to volatile/derivatizable analytes; lengthy derivatization |
| CE-MS | Electrophoretic mobility in capillary | Highly polar and ionic metabolites, nucleotides, organic acids | Excellent resolution for charged species, very low sample consumption | Lower sensitivity; migration-time reproducibility challenges |
| Ion mobility-MS | Gas-phase mobility in drift-field (orthogonal to LC or direct) | Lipid isomers, sugar isomers, structural isomers | Additional CCS descriptor improves identification confidence | Added complexity; CCS databases still growing |
| MALDI-/DESI-MSI | Direct desorption from tissue sections | Lipids, drug-related species, polar metabolites with available matrix | Spatial resolution (10–100 µm) | Lower quantitative accuracy; throughput bottleneck per section |
| SFC-MS | Supercritical CO2-based mobile phase with co-solvent gradient | Lipids, lipophilic species, chiral metabolites | Fast runs, low solvent consumption | Limited coverage of highly polar species |
Our LC-MS/MS team develops and validates targeted panels with isotope-dilution quantification for routine workflows.
Ion mobility spectrometry adds a gas-phase separation dimension to mass spectrometry by separating ions according to their collision cross section (CCS), a measure of the ion's size and shape in a buffer gas. In metabolomics, IMS-MS enhances identification confidence through CCS-based database matching, resolves isomers that chromatography cannot separate, and increases throughput when operated in flow-injection mode without chromatographic separation.
In an IMS stage, ions drift through a buffer gas under the influence of a weak electric field. Smaller, compact ions traverse the drift region faster than larger or more elongated ions with the same charge, so the drift time encodes structural information orthogonal to mass and chromatographic retention. When coupled to LC, IMS is placed after the chromatographic column and before the mass analyzer, providing a millisecond-scale separation layered onto the seconds-scale chromatographic separation. The drift time is converted into a CCS value, which serves as a reproducible, instrument-independent identifier of the ion.
Several drift geometries are deployed in current metabolomics instruments, including drift-tube ion mobility spectrometry (DT-IMS), traveling-wave ion mobility spectrometry (TW-IMS), trapped ion mobility spectrometry (TIMS), and structures for lossless ion manipulation (SLIM). All provide CCS values, although resolution and drift-time precision vary.
IMS-MS provides four-dimensional identification through accurate mass, retention time, MS/MS fragmentation, and CCS, raising confidence levels for metabolite identification closer to MSI Level 2 than is possible with only mass and fragmentation. The technique separates many biologically important isomers that LC cannot resolve: cis/trans lipid double-bond positional isomers, sn-1/sn-2 glycerolipid positional isomers, and many sugar and nucleotide isomers. In flow-injection mode without chromatography, IMS-MS achieves throughput several-fold higher than conventional LC-MS, enabling population-scale screening.
The main practical challenges are the still-developing CCS database coverage for metabolites, which limits immediate library matching for many species, and the added complexity of data acquisition and processing that can slow method development. Sensitivity is comparable to LC-MS only when IMS is added on top of LC; in flow-injection mode without chromatography, matrix effects can dominate and must be controlled through dilution or rapid cleanup. CCS reproducibility across instrument classes is improving but still requires careful standardization for cross-laboratory comparison.
IMS-MS is increasingly applied to lipidomics for fine-structure elucidation, including separation of fatty-acid chain-length isomers, double-bond positional isomers, and sn-positional isomers in glycerolipids, all of which carry biological meaning that is lost when only m/z is available. The platform is also valuable in metabolite annotation workflows where CCS values help distinguish candidate structures with identical molecular formulas but different shapes, particularly among sugars, nucleotides, and conjugated metabolites. High-throughput flow-injection IMS-MS supports rapid population screening for stratified cohort studies, and targeted IMS-MS methods add isomer specificity to routine panels used for biomarker validation studies, lipid subclass profiling, and pharmacokinetic studies of isomeric drugs or metabolites.
Our IMS-MS team supports lipid fine-structure analysis, CCS-based annotation, and high-throughput screening workflows.
Mass spectrometry imaging (MSI) maps the spatial distribution of metabolites across a tissue section by ionizing analytes directly from the surface and recording mass spectra at each pixel. Unlike solution-based methods, MSI preserves anatomical context, allowing researchers to see not only which metabolites are present in a sample but also where they are concentrated within the tissue.
Matrix-assisted laser desorption/ionization (MALDI) MSI applies a fine mist of matrix compound to a tissue section, then raster-fires a laser across the surface, ionizing analytes at each pixel and collecting a mass spectrum. The matrix absorbs the laser energy and transfers charge to the analyte, with pixel sizes routinely between 10 and 100 micrometers and newer instruments achieving single-digit micrometer resolutions for subcellular studies. Desorption electrospray ionization (DESI) MSI and related ambient ionization techniques, including SIMS and LAESI, omit the matrix step entirely and apply solvent or charged-droplet beams to the surface, allowing direct analysis under ambient conditions.
In both modalities, the recorded ion image is constructed by plotting signal intensity versus pixel coordinates for each m/z or each identified metabolite. The result is a spatial intensity map across the entire section that can be overlaid on the optical image of the tissue and correlated with histological stains or with region annotations such as tumor margin, necrotic core, or cortex versus medulla.
MSI's defining capability is spatially resolved metabolite mapping without labels or antibodies, providing an unbiased view of the chemical composition of a tissue that preserves its native architecture. The technique requires no a priori selection of targets, so both known and unexpected metabolites can be visualized once identified. Spatial resolution has improved steadily, with current MALDI platforms operating in the low micrometer range and DESI providing complementary coverage for more polar analytes.
Quantification remains a challenge: ionization efficiency varies with the local matrix environment, and absolute concentrations are difficult to extract without in-tissue calibration curves using matrix-matched standards. A single MSI acquisition for a tissue section may take hours, limiting throughput, and metabolite coverage depends on the ionization technique chosen; lipids and certain drug-related species are detected well by MALDI, while very polar metabolites remain difficult. Sample preparation requires careful attention to maintain metabolite integrity, avoid delocalization, and reconcile MSI images with histology.
MSI is widely used to study tumor metabolic heterogeneity, mapping lipids, amino acids, and drug-related species across tumor boundaries and adjacent healthy tissue to identify metabolites associated with specific regions. The technique supports drug-distribution studies by visualizing the spatial distribution of a candidate compound and its metabolites across organs without labels, often paired with pharmacokinetic readouts. Plant metabolism is another strong application, since MALDI-MSI can localize metabolites to root, leaf, seed, or vascular regions, providing a chemical atlas of tissues that complements bulk extraction measurements. MSI is also increasingly combined with histological annotation and spatial transcriptomics to construct multidimensional maps of tissues, where each modality contributes its own lens on the underlying biology.
Discuss tissue preparation, spatial resolution, and target metabolites with our MSI specialists.
Supercritical fluid chromatography uses supercritical CO2 as the main mobile-phase component, supplemented by polar co-solvents such as methanol or isopropanol. The low viscosity and high diffusivity of supercritical CO2 enable rapid and high-resolution separations that complement reversed-phase LC-MS, especially for lipid isomers and other moderately lipophilic metabolites.
In SFC, the mobile phase begins as liquid CO2, which is brought above its critical pressure and temperature to achieve supercritical-state behavior that combines gas-like diffusivity with liquid-like solvating power. A pressure or co-solvent gradient modulates eluting strength, with methanol or other modifiers added to elute increasingly polar analytes. The eluent passes through a low-volume column, exits the back-pressure device, and is delivered to a mass spectrometer through APCI or ESI sources that handle the high proportion of CO2 effectively.
For lipid-focused metabolomics, SFC separates species by class, chain length, and unsaturation efficiently within short run times, often five to ten minutes per sample. Chiral SFC, using chiral stationary phases, extends the platform to enantiomeric metabolites where stereochemistry carries biological meaning.
SFC-MS combines fast separations, modest solvent consumption, and excellent isomer resolution, particularly for lipids. Triglyceride, cholesteryl ester, and diglyceride analyses benefit from class-specific separations within a single run, while chiral SFC provides orthogonal selectivity for distinguishing enantiomers that cannot be resolved by reversed-phase LC. The technique integrates with mass spectrometry instruments through standard APCI and ESI sources, making it a straightforward addition to a metabolomics platform.
Highly polar analytes such as sugars, amino acids, and nucleotides are difficult to retain in SFC because the supercritical CO2 mobile phase lacks the strong polar interactions needed for their elution. The platform therefore complements rather than replaces reversed-phase LC for these analytes. Method transfer between SFC instruments requires attention to back-pressure device behavior and mobile-phase composition, and SFC should be treated as a specialized addition to a metabolomics platform rather than a universal solution.
SFC-MS is most strongly used in lipidomics, where the technique separates neutral lipids (triglycerides, cholesteryl esters, diglycerides) by chain length and unsaturation within minutes, and complements the polar-lipid coverage of reversed-phase LC-MS. The platform also serves chiral metabolomics, supporting enantioselective profiling of chiral metabolites and drug-related species where stereochemistry influences bioactivity. With its short cycle time, SFC-MS is well suited for high-throughput screening applications in pharmaceutical research, particularly during the lipid-related pathway studies that accompany pharmaceutical candidate evaluation.
Discuss SFC-MS workflow options, turnaround, and lipid-class coverage with our analytical team.
BOC Sciences operates an integrated metabolomics and metabolite analysis capability built around the platforms described in this article. The laboratory brings together NMR, LC-MS, LC-MS/MS, GC-MS, CE-MS, ion mobility, and mass spectrometry imaging instrumentation within a single analytical environment, supported by experienced method-development scientists, established reference standards, and a stable isotope labeling program. Programs are designed around the analytical question, beginning with platform selection matched to the metabolite classes of interest, and proceeding through sample preparation, data acquisition, identification, quantification, and biological interpretation.
Quantitative and tracer-based metabolomics depend on well-characterized isotope-labeled metabolites, and BOC Sciences supplies this foundation through a comprehensive stable isotope labeling program (listed in the service table). The catalog covers 13C, 15N, 2H (deuterium), and 18O labels across central-carbon metabolites, amino acids, organic acids, lipids, and nucleotides, with reference standards and tracer substrates available at defined isotopic enrichment and chemical purity. Custom isotope-labeled compounds can be developed for project-specific needs (see the service table), including precursors for pathway-tracing experiments.
The metabolite analysis and identification service (summarized in the service table below) combines untargeted and targeted workflows with multi-platform support. Untargeted HRMS profiling is delivered with full feature extraction, statistical analysis, and tiered identification using accurate mass, MS/MS libraries, CCS where available, and authentic standard confirmation. Targeted panels cover major metabolite classes such as amino acids, organic acids, bile acids, acylcarnitines, neurotransmitters, and vitamins, with both absolute and relative quantification options.
For programs that require more than a routine panel, our team provides hyphenated spectroscopic support across LC-MS, LC-MS/MS, GC-MS, CE-MS, and NMR for problem-driven identification, structure elucidation, and cross-platform validation. The work integrates our broader spectroscopy testing capabilities and isotope-labeled internal standards into single projects, providing clients with a coordinated answer to complex metabolite questions while keeping sample handoffs minimal.
Table.5 BOC Sciences Analytical Services Supporting Metabolomics and Metabolite Analysis.
| Service Name | Description | Inquiry |
| Metabolite Analysis and Identification | Untargeted HRMS profiling and targeted LC-MS/MS panels with multi-platform support for metabolite identification and quantification. | Inquiry |
| Stable Isotope Labeling | 13C, 15N, 2H, and 18O-labeled metabolites and reference standards for quantitative and tracer-based metabolomics. | Inquiry |
| NMR Testing | 1H, 2D, and HR-MAS NMR workflows for biofluid profiling, tissue metabolomics, and structure elucidation. | Inquiry |
| LC-MS Testing | Reversed-phase and HILIC LC-HRMS profiling for broad untargeted metabolomics and lipidomics workflows. | Inquiry |
| LC-MS/MS Testing | Targeted MRM panels for amino acids, bile acids, acylcarnitines, vitamins, neurotransmitters, and pathway-focused biomarkers. | Inquiry |
| GC-MS Testing | Derivatized primary-metabolite profiling and headspace or SPME workflows for volatile metabolite analysis. | Inquiry |
| Spectroscopy Testing | Complementary spectroscopic characterization integrated with mass spectrometry for structure confirmation and validation. | Inquiry |
| Hyphenated Spectroscopic Techniques | LC-MS, LC-NMR, and related coupled approaches for difficult identifications and cross-platform confirmation. | Inquiry |
| Metabolites Synthesis | Custom synthesis of metabolites, analogs, and reference standards needed for method development and confirmation. | Inquiry |
Table.6 Selection of Metabolomics Approaches Based on Biological Question and Sample Type.
| Biological Question | Representative Samples | Recommended Primary Approach | Recommended Complementary Approach |
| Broad discovery in heterogeneous populations | Plasma, serum, urine, tissue extracts | LC-HRMS untargeted profiling | NMR for cross-platform validation |
| Quantitative validation of candidate metabolites | Plasma, tissue, cell pellets | Targeted LC-MS/MS with isotope dilution | Stable isotope tracer to confirm pathway context |
| Primary carbon and nitrogen metabolite survey | Plant tissue, microbial cultures, biofluids | Derivatized GC-MS (primary metabolite panel) | LC-MS/MS for non-volatile extensions |
| Energy metabolites and redox cofactors | Tissue, cells, mitochondria | CE-MS for nucleotides and phosphorylated intermediates | LC-MS/MS for steady-state confirmation |
| Lipid subclass and isomer differentiation | Plasma, tissue, lipid extracts | IMS-MS or SFC-MS | Reversed-phase LC-MS for broad lipid coverage |
| Localized drug and metabolite distribution | Tissue sections, organ slices | MALDI-MSI or DESI-MSI | LC-MS/MS of homogenized tissue for absolute quantitation |
| Isomer-resolved neurotransmitter or sugar analysis | Cerebrospinal fluid, brain tissue, plant extracts | IMS-MS with targeted MS/MS | NMR for definitive structural confirmation |
| Pathway flux in live cells or animals | Cell cultures, tissues, biofluids after tracer administration | LC-MS or GC-MS of isotopologue distributions | NMR for tracer fate in complex metabolites |
Tell us your sample type, metabolite classes, study objective, and required level of identification or quantification. Our team can help design a fit-for-purpose single-platform or multi-platform analytical strategy.
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
